News & Events

Press releases

Pneumagen appoints James Noble, a highly experienced biotech leader, as Chairman of its Board of Directors

READ MORE...

Pneumagen Creates International Clinical Advisory Group of World Leading Respiratory and Infectious Disease Experts

READ MORE...

Pneumagen Announces First Patient Dosed in Phase 2 Proof of Concept Influenza Challenge Study Assessing Neumifil, an Intranasal Broad-Spectrum Antiviral

READ MORE...

Pneumagen Announces Positive Top Line Results from Phase 1 Study Evaluating Neumifil, a Product Designed for the Prevention and Treatment of Viral Respiratory Tract Infections

READ MORE...

Pneumagen Announces Appointment of John Beadle as Non-Executive Director

READ MORE...

Pneumagen to present on further significant development for its lead product, Neumifil at BioTrinity 2022

READ MORE...

Pneumagen Raises £3.8 million to Advance the Phase II Clinical Development of Neumifil, a Pan-antiviral, Intranasal Drug for the Prophylaxis and Treatment of Viral Respiratory Tract Infections (RTIs)

READ MORE...

Pneumagen initiates Phase 1 trial of Neumifil, a novel, intranasal pan anti-viral therapeutic for the prophylaxis and treatment of viral Respiratory Tract Infections

READ MORE...

Pneumagen Appoints New Head of Research to Expand its Anti-Viral Pipeline leveraging its Proprietary GlycoTarge™ Platform

READ MORE...

Event information

Bio€quity Europe in Dublin | May 14th – 16th 2023

READ MORE...

Biotech Showcase / JPM Week | January 9th – 11th 2023

READ MORE...

Jefferies London Healthcare Conference | November 15th – 17th 2022

READ MORE...

BIO-Europe in Leipzig | October 24th – 26th 2022

READ MORE...

BIO International Convention in San Diego | June 13th – 16th 2022

READ MORE...

Bio€quity Europe in Milan | May 16th – 18th 2022

READ MORE...

BioTrinity 2022 in London | April 26th – 27th 2022

READ MORE...

BIO-Europe Spring Digital | March 28th – 30th 2022

READ MORE...